Skip to main content
VECTUS BIOSYSTEMS LIMITED logo

VECTUS BIOSYSTEMS LIMITED — Investor Relations & Filings

Ticker · VBS ISIN · AU000000VBS9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 315 across all filing types
Latest filing 2020-07-26 Capital/Financing Update
Country AU Australia
Listing ASX VBS

About VECTUS BIOSYSTEMS LIMITED

https://vectusbiosystems.com.au/

Vectus Biosystems Limited is a drug discovery and development company focused on creating therapeutic candidates for the treatment of fibrosis and hypertension. The company utilizes a proprietary library of mimetic compounds to address tissue scarring and organ damage in the heart, kidneys, and liver. Its lead drug candidate, VB0004, is designed to treat high blood pressure and reverse established fibrosis. Complementing its pharmaceutical research, the company developed the Accugen platform, which provides a system for the precise quantification of DNA and RNA through quantitative polymerase chain reaction (qPCR) technology. By focusing on the reversal of fibrotic damage rather than symptom management, the company seeks to address significant unmet needs in chronic disease management and regenerative medicine.

Recent filings

Filing Released Lang Actions
Issue of Options 14 pages 821.8KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 27 July 2020 from Vectus Biosystems Limited regarding the issuance of 500,000 options to Gleneagle Securities for corporate advisory and consulting services. It includes a detailed Appendix 3G form which is a notification of issue of equity securities. The content focuses on the issuance of new options, their terms, and compliance with the Corporations Act 2001. There are no financial statements, management discussion, or earnings data. The document is a regulatory announcement about a capital raising event through issuing options, not a full financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is not a brief notice or report publication announcement. Hence, the classification is CAP with high confidence.
2020-07-26 English
Appendix 4C - Quarterly Report 6 pages 296.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'QUARTERLY REPORT – APPENDIX 4C' and contains detailed financial data including consolidated statements of cash flows for the quarter ended 31 March 2020. It includes operating, investing, and financing cash flows, reconciliation of cash and cash equivalents, financing facilities, and estimated cash available for future operating activities. The document is over 11,000 characters, indicating it is a substantive report rather than a brief announcement. The content aligns with a quarterly financial report providing comprehensive financial data and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2020
2020-06-08 English
Appendix 4C - Quarterly Report 7 pages 527.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'QUARTERLY REPORT – APPENDIX 4C' and references compliance with ASX Listing Rule 4.7B, which mandates quarterly reporting. It contains detailed financial data including consolidated statements of cash flows for the quarter ended 31 March 2020, commentary on company activities during the quarter, and financing details. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is a full quarterly report rather than a brief announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2020
2020-04-29 English
Publication on Reversal of Kidney Fibrotic Damage 3 pages 243.0KB
Regulatory Filings Classification · 90% confidence The document is a press release announcing the publication of preclinical research data related to a therapeutic peptide for kidney fibrosis. It discusses scientific study results, the significance of the findings, and the company's development plans. There is no indication of financial data, regulatory filings, shareholder information, or corporate governance content. The document is not a financial report, earnings release, or regulatory filing. It is a scientific and corporate announcement about research progress and publication, which does not fit into any of the specific financial or regulatory filing categories. Therefore, the best fit is Regulatory Filings (RNS) as a general announcement category for miscellaneous filings that do not fit other categories.
2020-03-09 English
Half Year Report 20 pages 1.1MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report Half Year Ended 31 December 2019' and contains detailed financial statements, including profit and loss, financial position, cash flows, notes to the financial statements, directors' report, and auditor's review report. It covers a six-month period ending 31 December 2019, which is a period shorter than a full fiscal year. The document includes substantive financial data and analysis, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-02-27 English
Appendix 4C - Quarterly Report 6 pages 403.5KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'QUARTERLY REPORT – APPENDIX 4C' and references compliance with ASX Listing Rule 4.7B, which pertains to quarterly reporting for entities listed on the Australian Securities Exchange. It contains detailed financial data including cash flow statements, financing activities, and commentary on company activities for the quarter ended 31 December 2019. The document is comprehensive and includes actual financial statements and analysis for a period shorter than a full fiscal year (quarterly). Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length is over 13,000 characters, indicating it is a full report rather than a brief announcement or certification. Hence, the correct classification is IR with high confidence. Q2 2020
2020-01-30 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.